









































## Paula M. Jacobs, Ph.D.

---

33. Jacobs, PM, NCI Resources for Translational Molecular Imaging Research, Advanced Molecular Imaging and Its Clinical Translation, Oct 27-30, 2013
34. Jacobs, PM, NCI Programs in Translational Molecular Imaging Research, NIBIB Workshop on Clinical Translation of Molecular Imaging Probes and Technology Lister Hill Auditorium, National Institutes of Health, Bethesda, MD, August 2, 2013
35. Jacobs, PM, Moderator, FDA and NIH: Critical Concepts for Diagnostic Radiopharmaceutical Research. Society of Nuclear Medicine and Molecular Imaging, June 2013 Vancouver BC
36. Jacobs, PM Overcoming Regulatory Hurdles in Molecular Imaging: The NCI Experience, Society of Nuclear Medicine and Molecular Imaging June 2013 Vancouver BC
37. Jacobs, PM, Translational Molecular Imaging: Promises and Pitfalls, [6th Imaging in Drug Discovery and Development Conference](#), Boston MA **May 8-10, 2013**
38. Jacobs, PM, Moderator, NCI resources for Imaging Research, AACR Annual Meeting, Washington DC, April 6-10, 2013
39. Jacobs, PM, Facilitating Access to Investigational Imaging Agents, AACR Annual Meeting, Washington DC, April 6-10, 2013
40. Jacobs, PM, Lessons learned: NCI's PET INDs and F-18 NaF NDA, 34<sup>th</sup> Annual High Country Nuclear Medicine Conference, Vail, CO, March 2013
41. Jacobs, PM, New FDA Guidance: Investigational New Drug Applications (INDs) for Positron Emission Tomography (PET) Drugs, Bio/Pharmaceutical Imaging Forum, December 2012, Philadelphia, PA
42. Jacobs, PM, Translational Molecular Imaging: A View from the NCI, Radiological society of North America (RSNA), November 2012, Chicago, IL
43. Jacobs, PM, The National Cancer Institute's NExT Program, Molecular Imaging: Preclinical and Clinical Advances, Harvard Medical School, October 2012, Boston, MA
44. Jacobs, PM, Overcoming Regulatory Hurdles in Investigational Molecular Imaging: The NCI Experience, ADAPT Congress Session, September 2012, Washington, DC
45. Jacobs, PM, NCI's Initiative in INDs: Update on Investigational Radiopharmaceuticals, Society of Nuclear Medicine and Molecular Imaging, 2012 Annual Meeting, June 2012, Miami Beach, FL
46. Jacobs, PM, NCI Cancer Imaging Program Quantitative Imaging Network (QIN) & Network for Translational Research (NTR), Society of Nuclear Medicine and Molecular Imaging, 2012 Annual Meeting, June 2012, Miami Beach, FL

## Paula M. Jacobs, Ph.D.

---

47. Jacobs, PM, The Role of NIH/NCI in Molecular Imaging Trials.Society of Nuclear Medicine and Molecular Imaging, 2012 Annual Meeting, June 2012, Miami Beach, FL
48. Jacobs, PM, Axelrad J, Yang L, Gelovanni J, Challenges to Translational of Molecular Imaging and Therapy, Panel, 3<sup>rd</sup> Multimodality Cardiovascular Molecular Imaging Symposium, April 2012, Bethesda, MD
49. Jacobs, PM, Alternative Sources of Funding from the National Cancer Institute, 10<sup>th</sup> YHLC Business of Biotechnology, Yale University, March 2012, New Haven CO
50. Jacobs PM, Advances and opportunities in CNS imaging 18th Annual Neuro-Oncology and Blood-Brain Barrier Consortium Meeting, March 2012, Skamania WA
51. Jacobs, PM, Lessons learned: NCI's PET INDs and F-18 NaF NDA, 33<sup>rd</sup> Annual High Country Nuclear Medicine Conference, Steamboat Springs, CO, March 2012
52. Jacobs, PM, Translating Molecular Imaging into Phase 3 Trials, 5<sup>th</sup> EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer", Brussels, Belgium, October 2011
53. Jacobs PM, Strategies and Pathways: Translating Molecular Imaging Agents into Phase 3 and Beyond, Society of Nuclear Medicine 2011 Annual Meeting, San Antonio, June 2011
54. Chair: Bioimaging and Other Applications for Disease And Treatment Evaluation; 2010 Second Annual American Society for Nanomedicine Conference – October 14-16 – Potomac, Maryland
55. Moderator: Industry Panel on the logistical and regulatory issues of experimental PET agents; ACRIN Fall meeting, October 3, 2010 in Pentagon City
56. Jacobs, PM, Navigating the Regulatory Shoals: Transitioning Your Imaging Agent to the Clinic, Society of Nuclear Medicine 2010 Annual Meeting, Salt Lake City, June 2010
57. Jacobs, PM, Lessons learned: NCI's FLT F-18 IND and F-18 NaF NDA, Two Topic Imaging Workshop: Standards For Imaging Endpoints And Manufacturing Of PET Radiopharmaceutical Products In Clinical Trials, Bethesda, MD
58. Jacobs, PM, Accessing NCI Resources: Imaging Imaging Agent Development, NCI Translational Science Meeting, November, 2009, Vienna, VA
59. Jacobs, PM, What is an IND and How Does It Affect ACRIN Clinical Trials, ACRIN 2009 Fall Meeting, Pentagon City, VA, October 2009
60. Jacobs, PM, The NCI Cancer Imaging Program: Developing imaging tools for drug development, American Association for Cancer Research, 100<sup>th</sup> Annual Meeting, Denver, CO, April 2009

## **Paula M. Jacobs, Ph.D.**

---

61. Jacobs, PM, CMC Requirements in INDs, Society of Nuclear Medicine 2009 Winter Meeting, Clearwater, Florida, February 2009
62. Jacobs PM, Imaging Probes: Regulatory Guidelines, Availability, and Considerations for Research, ACRIN Fall Meeting, October 2008, Pentagon City VA
63. Jacobs PM, The IND Process: How to get your experimental drug into human trials, Fourteenth Annual Neuro-Oncology and Blood-Brain Barrier Consortium Meeting, March 2008, Skamania WA
64. Jacobs PM, Regulatory Considerations for Trials of Imaging Drugs and Devices: FDA, INDs, IDEs, RDRC, IRBs, DSMBs, CTEP, Radiological Society Of North America Clinical Trials Methodology Workshop, Scottsdale, Arizona January 5-11, 2008
65. Jacobs, PM, What's in an Investigational New Drug Application (IND)? Workshop: Clinical Development of Small Molecules National Cancer Institute, January 2008 Bethesda, Maryland
66. Jacobs, PM, Economics of Contrast Agent Development, The Molecular Imaging Biomarker Development and Clinical Trials, Clinical Pre-conference at AMI-SMI Joint Meeting September 2007, Providence Rhode Island
67. Jacobs, PM, The IND Process and the Exploratory IND for Molecular Imaging Agent, The Molecular Imaging Biomarker Development and Clinical Trials Clinical Pre-conference at AMI-SMI Joint Meeting September 2007, Providence Rhode Island
68. Jacobs, PM, Nuts and Bolts--You Too Can Prepare an IND, Workshop, Phase 0 Trials in Oncologic Drug Development, Division of Cancer Treatment and Diagnosis, National Cancer Institute, September 5, 2007, Bethesda, MD
69. Jacobs PM, What is an IND and How Does It Affect ACRIN Clinical Trials. Presented to at the American College of Radiology Imaging Network meeting October 5- 7, 2006 Pentagon City, VA
70. Jacobs PM, Use Of Imaging Agents In Pediatric Cancer Management: Regulatory Issues, at the Pediatric Oncology Imaging Frontiers Workshop, Oct 23-24, 2006 Washington, DC
71. Jacobs PM, The IND Process and the Exploratory IND for Molecular Imaging Agents Academy of Molecular Imaging Meeting, March 29, 2006, Orlando FL. Presented in Session: Translational Molecular and Biomarker Development
72. Jacobs PM, Economics of Contrast Agent Development Academy of Molecular Imaging Meeting, March 29, 2006, Orlando FL. Presented in Session: Translational Molecular and Biomarker Development

## Paula M. Jacobs, Ph.D.

---

73. Jacobs, PM, Iron Oxide Drugs: Medical Uses for Rust, Radiology Research Conference, October 14, 2005, U. Mass. Medical School, Worcester, MA. Emphasis on MR imaging uses of iron oxides
74. (Oral Presentation and session moderator). Jacobs, PM, Cell and Molecular Imaging in the CNS, Eleventh Annual Neuro-Oncology and Blood-Brain Barrier Consortium Meeting, March 2005, Portland, OR.
75. Short presentation on the economics of imaging agents at the 6<sup>th</sup> National Forum on Biomedical Imaging in Oncology, April 7-8, 2005, Bethesda, MD. .  
<http://www.cancer.gov/dctd/presentations05.html>
76. Confidential invited lecture September 2000 to FDA: "Iron Oxide Drugs: Medical Uses for Rust." Seminar presented at the FDA at the invitation of a reviewing chemistry group, emphasis on chemistry and manufacturing of nanoparticle iron oxide drugs.